| Literature DB >> 35657571 |
Karine Naves Oliveira Goulart1,2, Cândido Celso Coimbra3, Helton Oliveira Campos3,4, Lucas Rios Drummond3, Pedro Henrique Madureira Ogando5, Georgia Brown6, Bruno Pena Couto7, Rob Duffield6,8, Samuel Penna Wanner5.
Abstract
BACKGROUND: This study aimed to analyze the extent of fatigue responses after female soccer matches and the ensuing recovery time course of performance, physiological, and perceptual responses.Entities:
Keywords: Cortisol; Countermovement jump; Creatine kinase; Estradiol; Female soccer; Muscle soreness; Performance; Recovery; Women
Year: 2022 PMID: 35657571 PMCID: PMC9166924 DOI: 10.1186/s40798-022-00466-3
Source DB: PubMed Journal: Sports Med Open ISSN: 2198-9761
Fig. 1Flow chart of study inclusion process
Description of the studies included in the systematic review
| Anthropometric characteristics | Match conditions | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study | N | Age (years) | Height (cm) | Body mass (kg) | Body fat (%) | VO2max (ml.kg−1.min−1) | Level | Period | Time playing (min) | Environment |
| Ai Ishida et al. [ | 12 | 20.7 ± 2.3 | 164.5 ± 6.0 | 64.4 ± 7.2 | ||||||
| Andersen et al. [ | 27 | Denmark: 22 ± 2 Norway: 21 ± 6 | Denmark: 169 ± 7 Norway: 170 ± 7 | Denmark: 61 ± 7 Norway: 62 ± 7 | HL | 90 | ||||
| Andersson et al. [ | 17 | Active recovery: 22.6 ± 4.2 Passive recovery: 21.6 ± 2.6 | Active recovery: 167.1 ± 5.7 Passive recovery: 167.2 ± 4.7 | Active recovery: 63.3 ± 7.1 Passive recovery: 65.0 ± 4.6 | Active recovery: 55.4 ± 3.6 Passive recovery: 53.8 ± 2.3 | E | 90 | 12 °C, light rain | ||
| Andersson et al. [ | 10 | 23 ± 13 | 167 ± 19 | 64 ± 19 | 54 ± 3 | E | Mid-season | 90 | 12 °C, light rain | |
| Bonilla et al. [ | 14 | 27.8 ± 5.0 | 176.1 ± 4.1 | 71.6 ± 3.3 | 18.5 ± 3.5 | HL | ||||
| Broodryk et al. [ | 8 | 23.1 ± 3.2 | 158.9 ± 6.4 | 54.7 ± 4.2 | C | 90 | 23 °C | |||
| Casanova et al. [ | 18 | 23.1 ± 4.3 | 169.4 ± 5.4 | 58.2 ± 4.3 | E | Early season | Minimum 10 | |||
| Casanova et al. [ | 20 | 22.9 ± 4.2 | 170.2 ± 5.7 | 59.3 ± 4.6 | 18.7 ± 3.1 | E | Early season | |||
| Casto et al. [ | 25 | 18–22 | C | |||||||
| Casto et al. [ | 25 | 18–22 | C | |||||||
| Edwards [ | 18 | 18–22 | C | End of season | ||||||
| Goulart et al. [ | 10 | 25.1 ± 5.9 | 162.0 ± 6.0 | 58.9 ± 6.2 | 17.9 ± 3.3 | 48.8 ± 0.4 | E | Regular season | 84.0 ± 14.5 | 33 ± 5 °C, 39 ± 13% RH |
| Gravina et al. [ | 28 | elite: 25 ± 5 sub-elite: 18.3 ± 1.5 | elite: 61.0 ± 7.4 sub-elite: 61.9 ± 9.8 | elite: 15.5 ± 2.9 sub-elite: 18.4 ± 3.3 | E/HL | |||||
| Haneishi et al. [ | 20 | starters: 20.2 ± 2.0 nonstarters: 20.5 ± 1.7 | starters: 166 ± 7.7 nonstarters: 166 ± 4.6 | starters: 58.3 ± 7.3 nonstarters: 64.6 ± 5.8 | starters: 16.6 ± 4.8 nonstarters: 19.1 ± 2.5 | C | Regular season | 21 °C, 30% RH | ||
| Hassmen and Blomstrand [ | 9 | 22.1 ± 3.6 | E | Regular season | ||||||
| Hoffman et al. [ | starters: 9 nonstarters: 10 | starters: 20.0 ± 1.0 nonstarters: 18.2 ± 0.4 | starters: 162.4 ± 3.8 nonstarters: 164.2 ± 7.8 | starters: 57.7 ± 4.7 nonstarters: 62.1 ± 8.3 | HL | End of season | starters: 56.5 ± 14.0 nonstarters: 29.0 ± 13.9 | 7 °C, 30% RH | ||
| Hughes et al. [ | U17: 12 | U17: 15.8 ± 0.3 | U17: 166.8 ± 3.4 | U17: 58.6 ± 4.7 | E | Regular season | U17: 90 | 7 °C, 72% RH | ||
| Krustrup et al. [ | 14 | 23 (18–29) | 169 (159–180) | 60.1 (53.3–69.5) | 18.5 (12.7–27.6) | 52.3 ± 1.3 | E | Regular season | ||
| Maya et al. [ | 16 | 22.5 ± 2.1 | 163 ± 7 | 59.5 ± 6.3 | E | End of season | 90 | |||
| Oliveira et al. [ | 33 | 24.2 ± 4.8 | E | End of season | 90 | |||||
| Pavin et al. [ | 20 | 20.6 ± 3.9 | 164 ± 4 | 59.6 ± 11.6 | R | 90 | 29 °C, 45% RH | |||
| Póvoas et al. [ | high-rank players = 6 low-rank players = 7 | 26 ± 4 | 170 ± 4 | 63.4 ± 4.8 | E | Pre-season (high-rank team players) Mid-season (low-rank team players) | 77 ± 15 | 21–22 °C, 50–70% RH | ||
| Scott et al. [ | CB: 8 FB: 6 CM: 15 WM: 3 F: 4 | CB: 25.3 ± 3.2 FB: 24.1 ± 3.6 CM: 24.5 ± 4.1 WM: 23.2 ± 5.2 F: 25.1 ± 4.9 | CB: 170.5 ± 7.1 FB: 168.5 ± 6.2 CM: 167.5 ± 5.3 WM: 166.0 ± 7.1 F: 168.7 ± 5.2 | CB: 66.0 ± 5.1 FB: 62.1 ± 4.2 CM: 62.3 ± 4.1 WM: 61.6 ± 5.1 F: 62.7 ± 6.1 | E | 90 | ||||
| Snyder et al. [ | 8 | 168.3 ± 5.6 | 63.5 ± 6.3 | E | 77.5 ± 8.9 | |||||
| Souglis et al. [ | 21 | 22.9 ± 2.4 | 168 ± 3 | 61.0 ± 3.3 | 15.2 ± 1.0 | 52.0 ± 1.8 | E | Regular season | 17–20 °C, 40–50% RH | |
| Souglis et al. [ | DEF: 10 MID: 10 ATT: 10 | DEF: 25.3 ± 3.2 MID: 24.7 ± 3.9 ATT: 23.9 ± 3.0 | DEF: 170 ± 3 MID: 168 ± 3 ATT: 170 ± 3 | DEF: 60.0 ± 1.4 MID: 58.3 ± 2.5 ATT: 59.4 ± 3.6 | DEF: 19.6 ± 1.0 MID: 18.2 ± 0.7 ATT: 19.1 ± 1.0 | DEF: 52.1 ± 1.9 MID: 55.4 ± 1.6 ATT: 53.2 ± 2.6 | E | Regular season | 14–20 °C, 40–60% RH | |
| Tsubakihara et al. [ | 18 | 161.2 ± 4.1 | 56.2 ± 5.1 | 22.2 ± 6.3 | C | 90 |
A= amateur; ATT= attackers; C= college; CB= center back; CM= center midfield; DEF= defenders; E= elite; F= forward; FB= full back; HL= high level; MID= midfielders; R= recreational; RH= relative humidity; and WM= wide midfield. Values are as mean ± standard deviation or as mean (range)
Fatigue and recovery time course of performance parameters
| Performance parameters | |||||||
|---|---|---|---|---|---|---|---|
| Study | Variable | Pre | Post | 1–12 h | 13–24 h | 25–48 h | 49–72 h |
| Ai Ishida et al. [ | CMJ height (cm) | 25.4 ± 4.7 | 22.3 ± 4.5* | 24.9 ± 4.6 | |||
| CMJ peak force (N) | 739.6 ± 92.8 | 714.0 ± 66.8 | 718.2 ± 73.4 | ||||
| CMJ peak power (W) | 2666 ± 154 | 2541 ± 156* | 2632 ± 165 | ||||
| Andersen et al. [ | YoYoIE1 (m) | 1480 ± 396 | 1025 ± 337* | ||||
| Andersson et al. [ | 20 m sprint (s) | ||||||
| Match 1—Active group | 3.18 ± 0.12 | 3.26 ± 0.12* | Missing | Missing | Missing | 3.17 ± 0.12 | |
| Match 1—Passive group | 3.17 ± 0.12 | 3.28 ± 0.16* | Missing | Missing | Missing | 3.15 ± 0.16 | |
| Match 2—Active group | 3.17 ± 0.12 | 3.25 ± 0.08 | |||||
| Match 2—Passive group | 3.15 ± 0.16 | 3.23 ± 0.12 | |||||
| CMJ height (cm) | |||||||
| Match 1—Active group | 30.5 ± 3.4 | 29.1 ± 2.9* | 29.4 ± 2.9 | 28.9 ± 2.5 | 29.2 ± 3.4 | 29.2 ± 3.1* | |
| Match 1—Passive group | 29.8 ± 3.7 | 28.4 ± 3.0* | 29.9 ± 2.9 | 29.3 ± 3.2 | 29.1 ± 3.6 | 28.9 ± 3.6* | |
| Match 2—Active group | 29.2 ± 3.1 | 28.6 ± 3.2 | |||||
| Match 2—Passive group | 28.9 ± 3.6 | 28.4 ± 3.8 | |||||
| Peak torque flexion (°. s−1) | |||||||
| Match 1—Active group | 102 ± 21 | 93 ± 25* | Missing | Missing | Missing | 101 ± 21 | |
| Match 1—Passive group | 104 ± 21 | 95 ± 21* | Missing | Missing | Missing | 104 ± 21 | |
| Match 2—Active group | 101 ± 21 | 96 ± 11 | |||||
| Match 2—Passive group | 104 ± 21 | 98 ± 12 | |||||
| Peak torque extension (°. s−1) | |||||||
| Match 1—Active group | 175 ± 21 | 165 ± 25* | Missing | Missing | Missing | 170 ± 25 | |
| Match 1—Passive group | 167 ± 16 | 154 ± 21* | Missing | Missing | Missing | 160 ± 25 | |
| Match 2—Active group | 170 ± 25 | 166 ± 14 | |||||
| Match 2—Passive group | 160 ± 25 | 154 ± 21 | |||||
| Bonilla et al. [ | CMJ height (cm) | 24.7 ± 3.2 | 24.9 ± 3.9 | 23.4 ± 4.0* | |||
| CMJ peak power (W) | 2139 ± 347 | 2154 ± 334 | 2059 ± 349 | ||||
| Goulart et al. [ | CMJ (cm) | 29.54 ± 2.56 | 28.01 ± 1.56# | 28.93 ± 1.89 | 29.81 ± 1.55 | ||
| 20 m sprint (s) | 3.34 ± 0.07 | 3.466 ± 0.12# | 3.422 ± 0.09# | 3.366 ± 0.07# | |||
| 10 m sprint (s) | 1.94 ± 0.03 | 1.979 ± 0.075 | 1.968 ± 0.070 | 1.941 ± 0.043 | |||
| Hoffman et al. [ | SJ peak power (W) | ||||||
| Starters | 3144 ± 656 | 3167 ± 502 | 2754 ± 776 | ||||
| Nonstarters | 3453 ± 546 | 3559 ± 423 | 3398 ± 679 | ||||
| CMJ peak power (W) | |||||||
| Starters | 3087 ± 438 | 2931 ± 477 | 2608 ± 411* | ||||
| Nonstarters | 3352 ± 593 | 3433 ± 604 | 3229 ± 656 | ||||
| SJ peak force (N) | |||||||
| Starters | 1014 ± 115 | 1016 ± 80 | 919 ± 151 | ||||
| Nonstarters | 1178 ± 276 | 1141 ± 171 | 1142 ± 182 | ||||
| CMJ peak force (N) | |||||||
| Starters | 923 ± 109 | 929 ± 128 | 836 ± 128 | ||||
| Nonstarters | 1097 ± 174 | 1111 ± 275 | 1047 ± 216 | ||||
Maximal rate of force development (kg × 103. s−1) | |||||||
| Starters | 17.0 ± 3.7 | 17.8 ± 4.3 | 16.5 ± 3.6 | ||||
| Nonstarters | 17.4 ± 3.3 | 17.4 ± 2.9 | 19.1 ± 3.4 | ||||
| Krustrup et al. [ | CMJ height (cm) | 35 ± 4 | 36 ± 4 | ||||
| 30 m sprint (s) | 4.86 ± 0.22 | 5.06 ± 0.22* | |||||
| YoYo IE2 (m) | 1265 ± 498 | 484 ± 187* | |||||
| Pavin et al. [ | T test agility (s) | 11.8 ± 0.5 | 12.8 ± 0.5* | ||||
| Heel-rise test (rep) | 35.4 ± 2.9 | 24.0 ± 4.0* | |||||
| YoYoIE2 (m) | 711.3 ± 93.1 | 496.0 ± 96.0* | |||||
| Snyder et al. [ | MVIC knee extension (kg) | ||||||
| Match 1 | 50.9 ± 8.0 | 47.9 ± 6.5 | 44.4 ± 7.8* | ||||
| Match 2 | 44.4 ± 7.8 | 47.4 ± 8.1 | |||||
| MVIC knee flexion (kg) | |||||||
| Match 1 | 43.5 ± 4.1 | 38.6 ± 6.8 | 43.4 ± 5.2 | ||||
| Match 2 | 43.4 ± 5.2 | 37.6 ± 6.3 | |||||
| CMJ height (cm) | |||||||
| Match 1 | 45.6 ± 6.9 | 44.0 ± 6.3 | 43.3 ± 6.0* | ||||
| Match 2 | 43.3 ± 6.0 | 43.3 ± 5.9 | |||||
CMJ= Countermovement jump; MVIC= maximum voluntary isometric contraction; SJ= squat jump; YoYoIE1= Yo−Yo intermittent endurance level 1; and YoYoIE2= Yo−Yo intermittent endurance level 2. *means significantly different from pre; # means significantly different from pre (time main effect). Significant differences were reported by the authors in the original studies. Missing values are data that could not be extracted by software and for which we had no response from the contacted authors. Values are as mean ± standard deviation
Fatigue and recovery time course of physiological parameters
| Physiological parameters | |||||||
|---|---|---|---|---|---|---|---|
| Study | Variable | Pre | Post | 1–12 h | 13–24 h | 25–48 h | 49–72 h |
| Andersson et al. [ | CK (U.L−1) | ||||||
| Match 1—Active group | 158 ± 136 | 344 ± 169* | Missing | Missing | 211 ± 128 | ||
| Match 1—Passive group | 146 ± 103 | 327 ± 214* | Missing | Missing | 157 ± 120 | ||
| Match 2—Active group | 211 ± 128 | 414 ± 161 | |||||
| Match 2—Passive group | 157 ± 120 | 363 ± 195 | |||||
| Bonilla et al. [ | CK (U/L) | 172 ± 54 | 169 ± 46 | ||||
| LDH (U/L) | 282 ± 44 | 341 ± 78* | |||||
| Gravina et al. [ | CK (U/L) | 150 ± 65 | 243 ± 148 | 332 ± 302* | |||
| LDH (U/L) | 317 ± 39 | 407 ± 68* | 342 ± 43 | ||||
| Póvoas et al. [ | CK (U/L) | ||||||
| Match 1—High-rank players | 230.8 ± 74.2 | 324.3 ± 124.7 | |||||
| Match 1—Low-rank players | 366.4 ± 319.3 | 563.0 ± 356.4 | |||||
| Souglis et al. [ | CK (U/L) | 145 ± 22 | 262 ± 55* | 747 ± 290* | 343 ± 185* | ||
| Souglis et al. [ | CK (U/L) | ||||||
| Attackers | 145.70 ± 17.99 | 254.50 ± 15.45 | 494.90 ± 84.51* | 422.20 ± 62.51* | 340.00 ± 49.12* | ||
| Midfielders | 146.50 ± 26.26 | 271.40 ± 24.20 | 539.10 ± 65.90* | 443.00 ± 62.39* | 363.80 ± 53.60* | ||
| Defenders | 132.30 ± 11.47 | 229.40 ± 23.74 | 407.80 ± 24.25* | 353.60 ± 25.82* | 309.20 ± 18.63* | ||
| LDH (IU/L) | |||||||
| Attackers | 155.90 ± 11.44 | 222.30 ± 13.60 | 332.00 ± 18.59* | 313.80 ± 16.05* | 246.10 ± 11.52* | ||
| Midfielders | 152.40 ± 9.41 | 240.40 ± 14.40 | 355.50 ± 17.13 | 322.80 ± 11.77* | 260.50 ± 14.06* | ||
| Defenders | 155.50 ± 11.07 | 214.80 ± 9.50 | 321.00 ± 13.93* | 307.70 ± 14.63* | 231.60 ± 10.78* | ||
| Tsubakihara et al. [ | CK (IU/L) | 210.3 ± 128.2 | 292.8 ± 152.2* | ||||
| LDH (IU/L) | 204.1 ± 47.5 | 261.9 ± 57.7* | |||||
| Andersson et al. [ | IL-6 (pg/mL) | ||||||
| Match 1—Active group | 2.1 ± 1.8 | 11.3 ± 8.3* | 6.0 ± 6.9 | 3.5 ± 2.0 | 3.9 ± 4.2 | ||
| Match 1—Passive group | 5.4 ± 3.4 | 9.8 ± 3.4* | 6.1 ± 4.7 | 4.2 ± 1.8 | 4.3 ± 5.6 | ||
| Match 2—Active group | 3.9 ± 4.2 | 10.6 ± 6.3 | |||||
| Match 2—Passive group | 4.3 ± 5.6 | 10.1 ± 6.9 | |||||
| TNF-α (pg/mL) | |||||||
| Match 1—Active group | 7 ± 2 | 24 ± 22* | 17 ± 9 | 8 ± 2 | 10 ± 4 | ||
| Match 1—Passive group | 9 ± 2 | 25 ± 7* | 14 ± 7 | 8 ± 2 | 15 ± 11 | ||
| Match 2—Active group | 10 ± 4 | 9 ± 2 | |||||
| Match 2—Passive group | 15 ± 11 | 17 ± 4 | |||||
| Leukocytes (cells/mL) | |||||||
| Match 1 | 5.3 ± 1.1 × 103 | 8.2 ± 1.5 × 103* | 4.8 ± 0.9 × 103 | ||||
| Match 2 | 4.8 ± 0.9 × 103 | 8.3 ± 1.8 × 103 * | |||||
| Neutrophils (cells/mL) | |||||||
| Match 1 | 3.0 ± 1.1 × 103 | 6.1 ± 1.5 × 103* | 2.7 ± 0.6 × 103 | ||||
| Match 2 | 2.7 ± 0.6 × 103 | 6.4 ± 1.7 × 103* | |||||
| Lymphocytes (cells/mL) | |||||||
| Match 1 | 1.8 ± 0.3 × 103 | 1.6 ± 0.4 × 103 | 1.6 ± 0.4 × 103 | ||||
| Match 2 | 1.6 ± 0.4 × 103 | 1.5 ± 0.1 × 103 | |||||
| Gravina et al. [ | CRP (mg/dL) | 0.06 ± 0.05 | 0.11 ± 0.04 | 0.16 ± 0.13* | |||
| Leukocyte (103/µL) | 5.35 ± 0.8 | 9.64 ± 2.9* | 5.81 ± 1.2 | ||||
| Neutrophils (103/µL) | 2.54 ± 0.6 | 7.35 ± 2.9* | 2.83 ± 0.8 | ||||
| Lymphocytes (103/µL) | 2.15 ± 0.5 | 1.62 ± 0.9* | 2.29 ± 0.6 | ||||
| Goulart et al. [ | CRP (mg/L) | 0.24 ± 0.19 | 0.73 ± 0.90 | 0.53 ± 0.57 | 0.38 ± 0.33 | ||
| Póvoas et al. [ | CRP (mg/L) | ||||||
| Match 1—High-rank players | 0.75 ± 4.46 | 1.28 ± 1.08 | |||||
| Match 1—Low-rank players | 0.96 ± 1.03 | 0.78 ± 0.64 | |||||
| Souglis et al. [ | CRP (mg/mL) | 1.37 ± 1.31 | 1.53 ± 1.12 | 3.03 ± 2.08* | 1.78 ± 1.33 | ||
| IL-6 (pg/mL) | 1.23 ± 0.71 | 5.09 ± 3.07* | 1.35 ± 0.88 | 1.18 ± 0.68 | |||
| TNF-α (pg/mL) | 1.89 ± 0.53 | 4.49 ± 1.27* | 2.18 ± 0.59 | 1.86 ± 0.60 | |||
| Souglis et al. [ | CRP (mg/L) | ||||||
| Attackers | 0.93 ± 0.26 | 1.13 ± 0.27 | 2.47 ± 0.59* | 1.16 ± 0.41 | 1.03 ± 0.34 | ||
| Midfielders | 0.91 ± 0.22 | 1.24 ± 0.31 | 2.88 ± 1.00* | 1.12 ± 0.49 | 0.99 ± 0.33 | ||
| Defenders | 0.99 ± 0.24 | 1.13 ± 0.29 | 2.27 ± 0.39* | 1.12 ± 0.29 | 1.04 ± 0.26 | ||
| IL-6 (pg/mL) | |||||||
| Attackers | 1.16 ± 0.15 | 3.54 ± 0.25* | 1.16 ± 0.15 | 1.16 ± 0.12 | 1.16 ± 0.10 | ||
| Midfielders | 1.15 ± 0.16 | 3.82 ± 0.22* | 1.16 ± 0.17 | 1.16 ± 0.07 | 1.16 ± 0.13 | ||
| Defenders | 1.16 ± 0.18 | 3.32 ± 0.22* | 1.14 ± 0.18 | 1.17 ± 0.14 | 1.17 ± 0.12 | ||
| Tsubakihara et al. [ | Leukocyte (/mL) | 5439 ± 1515 | 9497 ± 2621* | ||||
| Neutrophil (/mL) | 2915 ± 1285 | 7335 ± 2494* | |||||
| Lymphocyte (/mL) | 2009 ± 446 | 1631 ± 558* | |||||
| Broodryk et al. [ | Cortisol (nmoll/L) | ||||||
| Match 1 | 9.79 ± 3.37 | 52.65 ± 21.43* | |||||
| Match 2 | 16.22 ± 7.24 | 36.12 ± 16.07* | |||||
| Match 3 | 22.95 ± 7.96 | 30.00 ± 18.97 | |||||
| Match 4 | 12.09 ± 3.21 | 29.69 ± 20.51 | |||||
| Match 5 | 7.04 ± 3.67 | 36.73 ± 10.10* | |||||
| Match 6 | 6.73 ± 4.90 | 26.93 ± 15.00* | |||||
| Casanova et al. [ | Cortisol (mg/dL) | ||||||
| Match 1—PIP | 0.40 ± 0.13 | 0.42 ± 0.09 | |||||
| Match 1—GIP | 0.55 ± 0.16 | 0.64 ± 0.48 | |||||
| Match 2—PIP | 0.50 ± 0.13 | 0.38 ± 0.12* | |||||
| Match 2—GIP | 0.41 ± 0.11 | 0.49 ± 0.17 | |||||
| Match 3—PIP | 0.45 ± 0.19 | 0.45 ± 0.12 | |||||
| Match 3—GIP | 0.42 ± 0.09 | 0.33 ± 0.01 | |||||
| Match 4—PIP | 0.73 ± 0.18 | 0.55 ± 0.22 | |||||
| Match 4—GIP | 0.86 ± 0.20 | 0.60 ± 0.22 | |||||
| Testosterone (pg/mL) | |||||||
| Match 1—PIP | 51.17 ± 30.52 | 43.50 ± 21.44 | |||||
| Match 1—GIP | 74.71 ± 29.53 | 54.71 ± 31.23* | |||||
| Match 2—PIP | 83.63 ± 38.78 | 63.14 ± 14.77 | |||||
| Match 2—GIP | 77.60 ± 18.05 | 61.40 ± 18.60 | |||||
| Match 3—PIP | 68.78 ± 39.86 | 45.25 ± 22.33* | |||||
| Match 3—GIP | 72.33 ± 34.27 | 46.00 ± 14.80 | |||||
| Match 4—PIP | 64.75 ± 35.08 | 41.25 ± 18.71 | |||||
| Match 4—GIP | 59.63 ± 23.63 | 47.14 ± 22.79 | |||||
| T/C | |||||||
| Match 1—PIP | 118.76 ± 66.03 | 101.26 ± 30.34 | |||||
| Match 1—GIP | 136.86 ± 33.08 | 93.42 ± 23.39* | |||||
| Match 2—PIP | 170.32 ± 69.79 | 155.62 ± 40.92 | |||||
| Match 2—GIP | 193.08 ± 33.71 | 133.22 ± 48.77 | |||||
| Match 3—PIP | 164.43 ± 73.79 | 102.86 ± 58.34* | |||||
| Match 3—GIP | 176.55 ± 97.79 | 138.32 ± 45.95 | |||||
| Match 4—PIP | 84.45 ± 32.84 | 79.17 ± 27.53 | |||||
| Match 4—GIP | 71.14 ± 26.04 | 71.28 ± 28.27 | |||||
| Casanova et al. [ | Cortisol (mg/dL) | ||||||
| Match 1 | 0.48 ± 0.15 | 0.46 ± 0.12 | |||||
| Match 2 | 0.44 ± 0.12 | 0.39 ± 0.14 | |||||
| Match 3 | 0.44 ± 0.15 | 0.44 ± 0.15 | |||||
| Match 4 | 0.83 ± 0.20 | 0.61 ± 0.22* | |||||
| Testosterone (pg/mL) | |||||||
| Match 1 | 63.0 ± 29.4 | 50.30 ± 24.9* | |||||
| Match 2 | 78.1 ± 29.1 | 57.2 ± 21.1* | |||||
| Match 3 | 67.6 ± 34.5 | 48.8 ± 22.1* | |||||
| Match 4 | 63.5 ± 28.7 | 45.6 ± 19.5* | |||||
| Casto et al. [ | Cortisol (μg/dL) | ||||||
| Home-loss, no OC use | 0.47 ± 0.20 | 0.55 ± 0.21 | |||||
| Home-loss, OC use | 0.33 ± 0.12 | 0.77 ± 0.34 | |||||
| Away-win, no OC use | 0.43 ± 0.30 | 0.59 ± 0.25 | |||||
| Away-win, OC use | 0.33 ± 0.10 | 0.69 ± 0.22 | |||||
| Testosterone (pg/mL) | |||||||
| Home-loss, no OC use | 60.2 ± 15.1 | 81.2 ± 17.8 | |||||
| Home-loss, OC use | 49.2 ± 10.3 | 72.7 ± 24.2 | |||||
| Away-win, no OC use | 58.3 ± 20.4 | 93.0 ± 21.1 | |||||
| Away-win, OC use | 48.5 ± 9.1 | 71.6 ± 20.6 | |||||
| Estradiol (pg/mL) | |||||||
| Home-loss, no OC use | 3.71 ± 0.89 | 3.68 ± 0.70 | |||||
| Home-loss, OC use | 3.92 ± 0.95 | 4.03 ± 1.10 | |||||
| Away-win, no OC use | 3.27 ± 1.05 | 3.72 ± 1.00 | |||||
| Away-win, OC use | 3.66 ± 0.75 | 3.86 ± 0.91 | |||||
| Casto et al. [ | Cortisol (µg/dL) | ||||||
| Win | 0.36 ± 0.18 | 0.66 ± 0.23 | |||||
| Loss | 0.38 ± 0.16 | 0.69 ± 0.31 | |||||
| Testosterone (pg/mL) | |||||||
| Win | 51.8 ± 13.9 | 78.7 ± 22.5 | |||||
| Loss | 53.1 ± 12.9 | 75.7 ± 22.0 | |||||
| Edwards [ | Cortisol (ug/dL) | ||||||
| Winning game | 0.239 ± 0.143 | 0.485 ± 0.234* | |||||
| Losing game | 0.196 ± 0.076 | 0.451 ± 0.172* | |||||
| Testosterone (pg/mL) | |||||||
| Winning game | 18.40 ± 6.14 | 24.26 ± 7.77* | |||||
| Losing game | 17.02 ± 5.36 | 23.46 ± 8.66* | |||||
| Gravina et al. [ | Testosterone (ng/mL) | 0.57 ± 0.2 | 0.77 ± 0.3 | 0.56 ± 0.2 | |||
| Estradiol (ng/mL) | 68.8 ± 59 | 116 ± 102* | 101 ± 86 | ||||
| Haneishi et al. [ | Cortisol (nmol/L) | ||||||
| Starters | 18.0 ± 10.3 | 53.1 ± 33.9* | |||||
| Nonstarters | 12.5 ± 13.6 | 28.8 ± 32.5* | |||||
| Maya et al. [ | Cortisol (nmol/L) | ||||||
| Match 1 | 10.18 ± 1.54 | 22.07 ± 7.03* | 12.24 ± 4.49 | ||||
| Match 2 | 12.24 ± 4.49 | 16.49 ± 7.70 | |||||
| Testosterone (nmol/L) | |||||||
| Match 1 | 0.27 ± 0.07 | 0.39 ± 0.14* | 0.25 ± 0.36 | ||||
| Match 2 | 0.25 ± 0.36 | 0.36 ± 0.16* | |||||
| T/C ratio | |||||||
| Match 1 | 0.22 ± 0.08 | 0.15 ± 0.05* | 0.17 ± 0.07 | ||||
| Match 2 | 0.17 ± 0.07 | 0.19 ± 0.08 | |||||
| Oliveira et al. [ | Cortisol (ng/mL) | ||||||
| Winners | 2.55 ± 0.53 | 3.12 ± 0.82 | |||||
| Losers | 2.35 ± 0.23 | 3.00 ± 0.44 | |||||
| Testosterone (pg/mL) | |||||||
| Winners | 48.2 ± 10.8 | 92.2 ± 15.9* | |||||
| Losers | 41.4 ± 6.5 | 23.4 ± 1.8 * | |||||
CK= Creatine kinase; CRP= C-reactive protein; GIP= good individual performance; LDH= lactate dehydrogenase; OC= oral contraceptives; PIP= poor individual performance; T/C= testosterone/cortisol; and *means significantly different from pre. Significant differences were reported by the authors in the original studies. Missing values are data that could not be extracted by software and for which we had no response from the contacted authors. Values are as mean ± standard deviation
Fatigue and recovery time course of perceptual parameters
| Perceptual parameters | |||||||
|---|---|---|---|---|---|---|---|
| Study | Variable | Pre | Post | 1–12 h | 13–24 h | 25–48 h | 49–72 h |
| Andersson et al. [ | DOMS | ||||||
| Match 1—Active group | 2.8 ± 0.8 | 4.3 ± 0.4* | Missing | Missing | Missing | 3.5 ± 0.4 | |
| Match 1—Passive group | 3.1 ± 0.8 | 3.9 ± 0.8* | Missing | Missing | Missing | 3.1 ± 0.8 | |
| Match 2—Active group | 3.5 ± 0.4 | 4.8 ± 0.6 | |||||
| Match 2—Passive group | 3.1 ± 0.8 | 4.6 ± 0.6 | |||||
| Bonilla et al. [ | DOMS | 3.2 ± 1.7 | 4.9 ± 1.4* | 5.1 ± 1.7* | |||
| Broodryk et al. [ | Vigor | ||||||
| Match 1 | 3.8 ± 0.7 | 3.0 ± 0.9 | |||||
| Match 2 | 2.9 ± 0.8 | 3.3 ± 0.7 | |||||
| Match 3 | 3.3 ± 0.8 | 2.8 ± 0.9 | |||||
| Match 4 | 2.6 ± 0.9 | 3.4 ± 0.9 | |||||
| Match 5 | 3.4 ± 0.5 | 1.5 ± 0.8 | |||||
| Match 6 | 2.4 ± 0.8 | 2.6 ± 1.4 | |||||
| Fatigue | |||||||
| Match 1 | 1.5 ± 0.76 | 2.8 ± 1.2 | |||||
| Match 2 | 2.4 ± 1.3 | 2.5 ± 1.1 | |||||
| Match 3 | 3.1 ± 1.6 | 1.9 ± 1.3 | |||||
| Match 4 | 2.4 ± 1.7 | 1.6 ± 0.9 | |||||
| Match 5 | 2.4 ± 1.3 | 4.2 ± 1.0 | |||||
| Match 6 | 3.9 ± 0.7 | 2.5 ± 1.5 | |||||
| Goulart et al. [ | DOMS | 0.9 ± 1.7 | 2.9 ± 2.5* | 1.6 ± 1.8 | 0.7 ± 1.2 | ||
| Hassmen et al. [ | Vigor | ||||||
| Games won | 18.5 ± 4.2 | 15.0 ± 3.4 | 14.8 ± 4.8 | ||||
| Games tied | 20.4 ± 2.4 | 9.8 ± 4.2 | 13.3 ± 4.8 | ||||
| Games lost | 17.9 ± 5.4 | 7.9 ± 5.1 | 11.7 ± 7.0 | ||||
| Fatigue | |||||||
| Games won | 1.7 ± 0.8 | 12.8 ± 4.2 | 8.2 ± 4.5 | ||||
| Games tied | 1.8 ± 1.0 | 14.0 ± 2.4 | 8.3 ± 3.0 | ||||
| Games lost | 2.1 ± 0.9 | 11.2 ± 5.1 | 7.6 ± 4.7 | ||||
| Hughes et al. [ | DOMS | 0.85 ± 0.97 | 5.33 ± 2.52* | ||||
| Scott et al. [ | Soreness | 1.32 ± 0.78 | -0.74 ± 0.85 | 0.08 ± 0.88 | |||
| Fatigue | 1.50 ± 0.62 | -0.82 ± 0.97 | 0.20 ± 0.90 | ||||
DOMS= delayed onset muscle soreness. Data from Scott et al. [51] were not included in the meta-analyses since fatigue and soreness were reported as estimated marginal means. *means significantly different from pre. Significant differences were reported by the authors in the original studies. Missing values are data that could not be extracted by software and for which we had no response from the contacted authors. Values are as mean ± standard deviation
Fig. 2Effect size for analyses comparing post-match to pre-match physical performance parameters. Values are effect size (ES) and 95% confidence interval (CI). CMJ = Countermovement jump; YoYo = YoYo intermittent endurance test. Black circles represent no significant difference from pre. Gray squares represent significantly different from pre
Fig. 3Effect size for analyses comparing post-match to pre-match muscle damage markers. Values are effect size (ES) and 95% confidence interval (CI). CK = creatine kinase; LDH = lactate dehydrogenase. Gray squares represent significantly different from pre
Fig. 4Effect size for analyses comparing post-match to pre-match inflammatory parameters. Values are effect size (ES) and 95% confidence interval (CI). CRP = C-reactive protein. Black circles represent no significant difference from pre. Gray squares represent significantly different from pre
Fig. 5Effect size for analyses comparing immediately post-match to pre-match neuroendocrine parameters. Values are effect size (ES) and 95% confidence interval (CI). T/C = testosterone/cortisol ratio. Black circles represent no significant difference from pre. Gray squares represent significantly different from pre
Fig. 6Effect size for analyses comparing post-match to pre-match perceptual parameters. Values are effect size (ES) and 95% confidence interval (CI). DOMS = delayed onset muscle soreness. Black circles represent no significant difference from pre. Gray squares represent significantly different from pre
Qualitative assessment tool and average methodological quality scores of the 13 criteria
| Item | Qualitative assessment | |
|---|---|---|
| 1 | Was the study question or objective clearly described? | 1.98 ± 0.10 |
| 2 | Were the inclusion criteria stated? (e.g., players with previous injuries were excluded) | 1.37 ± 0.38 |
| 3 | Were the main outcomes to be measured clearly described in the introduction or methods section? | 1.95 ± 0.14 |
| 4 | Were the main outcomes measured using accurate procedures? (e.g., reliability was reported by means of assessment or citation) | 1.30 ± 0.68 |
| 5 | Were the players’ participation level (e.g., amateur), training background (e.g., years of training), training status (e.g., training hours or sessions/ matches per week) described? | 1.46 ± 0.39 |
| 6 | Were the anthropometric characteristics described? (e.g., body mass, height, and body fat) | 1.60 ± 0.74 |
| 7 | Was the season period when the match took place stated? (e.g., off-season/ pre-season/ competitive-season) | 1.42 ± 0.78 |
| 8 | Was the ground surface specified? (e.g., grass/ artificial turf/ synthetic surface) | 0.22 ± 0.64 |
| 9 | Were the environmental conditions described? (e.g., temperature and humidity) | 0.72 ± 0.91 |
| 10 | Were external (e.g., time motion analyses/ performance measures) and internal (e.g., RPE/ heart rate) measures of match intensity recorded? | 0.85 ± 0.81 |
| 11 | Was the activity undertaken during the recovery period (e.g., 12–72 h post-match) described? (studies with only pre and immediately post-match measures were scored as 2) | 1.90 ± 0.29 |
| 12 | Was a limitation paragraph with possible confounding factors included in the study? | 1.24 ± 0.88 |
| 13 | Was the use of hormonal contraceptives or menstrual cycle phase reported? | 0.59 ± 0.93 |
| Total | 16.6 ± 3.0 |
Values are mean and standard deviation